 Home > Active Ingredient News > Endocrine System > Nat Med: Subcutaneous injection of exenatide and cardiovascular outcomes in patients with type 2 diabetes

Nat Med: Subcutaneous injection of exenatide and cardiovascular outcomes in patients with type 2 diabetes

 Last Update: 2021-12-26
 Source: Internet
 Author: User

Tags

gfsi food safety

journal parkinson's disease

6 3 nm

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Regular injection of glucagon-like peptide-1 receptor agonist (GLP-1RA) has been shown to not increase and, for certain cardiac blood vessels may reduce the patient's disease cardiovascular event risk
.

The cardiovascular safety of continuous subcutaneous infusion of GLP-1RA exenatide (ITCA650) is not yet clear

Vascular cardiovascular events

Recently, the top medical journal Nature Medicine published a research article in which researchers randomly assigned type 2 patients with atherosclerotic cardiovascular disease (ASCVD) or risk of atherosclerotic cardiovascular disease (ASCVD) Diabetic patients were treated with ITCA650 or placebo, and their cardiovascular safety was evaluated in this pre-approved trial (NCT01455896)
.

diabetes

The main outcome of the study was the composite outcome of cardiovascular death, non-fatal myocardial infarction , non-fatal stroke, or hospitalization due to unstable angina
.

According to the US Food and Drug Administration Bureau in 2008 guidelines , the researchers used a non-inferiority margin of 1.

Guidelines for the management of myocardial infarction and stroke

The researchers randomized 4156 patients (2075 were assigned to receive ITCA650 treatment and 2081 were assigned to receive placebo treatment), and the median follow-up time was 16 months
.

It can be seen that for type 2 diabetes with or associated with ASCVD risk, ITCA650 treatment is not inferior to placebo
.

Larger, longer-duration cardiovascular outcome trials are needed to more accurately define the cardiovascular effects of ITCA650 in this population

For type 2 diabetes with or associated with ASCVD risk, ITCA650 treatment is not inferior to placebo

Original source:

Christian T.

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Empagliflozin

CAS No.: 864070-44-0

Pharmacy Grade

$1134/KG FOB

Yohimbine hydrochloride 98% White crystalline powder

CAS No.: 65-19-0

Pharmacy Grade

$600-620/KG EXW

High Quality Semaglutide 99% powder 910463-68-2-Shaanxi Dideu Medichem Co.Ltd

CAS No.: 910463-68-2

Chemical Grade

$1/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.